Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-002: Lenvatinib + Pembrolizumab vs Lenvatinib for First-line Advanced Hepatocellular Carcinoma
jRCT2080224523Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing lenvatinib + pembrolizumab with lenvatinib + placebo (2 arms). Primary endpoints: Overall survival and Progression-free survival per RECIST 1.1 by BICR. Started Jan 2019; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080224523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224523.